Google Chrome
Safari
Firefox
Edge
Hovione Lumiar
Office and R&D Center
Search
Drug Substance Development
Talented people, smart processes and cutting-edge equipment – we have the perfect formula to meet all your process development and scale-up needs.
Press Clipping / Sep 23, 2020
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Business Wire, September 23, 2020
Continuous Flow
Expand the established chemistry space with Continuous Flow to deliver robust and sustainable processes.
Hydrogenations
Hovione has vast experience in developing hydrogenation processes using both heterogeneous and homogeneous catalysis.
Hovione Cork
Manufacturing Plant
Press Release / Sep 23, 2020
Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19
Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®
Drug Substance Technologies
We constantly innovate to find better, more efficient ways of doing things.
Cryogenics
Hovione has experience in carrying out reactions at low temperatures.